Learning Objectives:

1. Understand why the FDA gave early approval for the use of 17-OH progesterone to reduce the risk of recurrent preterm delivery

2. Appreciate subsequent studies of 17-OH progesterone and FDA recommendations


Session date: 
12/01/2022 - 8:00am to 9:00am CST
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Scott MacGregor DO